In conclusion, this study finds a novel GSK3β/FTO/MZF1/c‐MYC axis which is involved in the occurrence and development of CRC and, clinically, proposes a therapeutic regimen based on using GSK3β as the inhibitor for treating CRC patients, which may hold great potential to relieve CRC‐related pathogenic symptoms. Here, GSK3B is linked to colorectal carcinoma.